Health ❯ Pharmaceuticals ❯ Drug Development ❯ Clinical Trials

Monoclonal Antibodies

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

Investors must act today as cases focus on claims that sonelokimab was touted as superior before Phase 3 results coincided with a steep share collapse.

7 ARTICLES

last wk.

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

6 ARTICLES

last wk.

MoonLake Faces Expanding Securities Suits as Lead-Plaintiff Deadline Nears

10 ARTICLES

4w ago

MoonLake Investors Courted by Law Firms as Lead‑Plaintiff Deadline Nears in SDNY Securities Case

6 ARTICLES

last mo.

MoonLake Investors Face Dec. 15 Deadline in Securities Suits Over Sonelokimab Claims

6 ARTICLES

2mo ago

MoonLake Faces Securities Class Action After SLK Trial Miss as Firms Seek Lead Plaintiff